Biocontainment Laboratory—Rutgers University

Biocontainment Laboratory—Duke University School of Medicine, Duke Human Vaccine Institute

Rocky Mountain Regional Biocontainment Laboratory—Colorado State University

Biocontainment Laboratory—University of Texas Medical Branch Galveston National Laboratory

Biocontainment Laboratory—Boston University National Emerging Infectious Diseases Laboratory

The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases. The mission of the NEIDL is to generate and translate fundamental knowledge on high priority emerging infectious diseases for the benefit of the public health, locally, nationally and globally.

Biocontainment Laboratory-George Mason University Institute for Biohealth Innovation

National and Regional Biocontainment Research Facilities

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.  

GCgx

Glucocorticoids are the cornerstone of anti-inflammatory and immunosuppressive therapy in humans. They are often the drugs of choice when rapid and potent control of an overactive immune system is necessary. This was exemplified recently by their successful use in the treatment of patients with severe COVID-19. Unfortunately, glucocorticoids also have serious side effects that affect every organ system, and each type of human cell has a very different response to glucocorticoids.

Notice of Special Interest (NOSI)—Administrative Supplement for Collaborative Projects Supported by the NIAID/RNCP

The purpose of this Notice of Special Interest (NOSI) is to highlight NIAIDs interest in supporting research aimed at fostering collaborations between researchers throughout the NIAID/Radiation and Nuclear Countermeasures Program (RNCP)-funded grant and cooperative agreement portfolio (e.g., U01, U19, R21, R01, P01). The NIAID/RNCP has been tasked with developing safe and effective medical countermeasures (MCMs) and biodosimetry tools for civilians that can be used at least 24 hours post-exposure in a radiological or nuclear public health emergency.

Diagnostics Development Services

NIAID’s Diagnostics Development Services program offers reagents, platform testing, and planning and design support to accelerate product development of in vitro diagnostics (IVD) for infectious diseases, from research feasibility through clinical validation.
Subscribe to